Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Am. Acad. Dermatol.

Title: Journal of the American Academy of Dermatology

Publisher: Elsevier BV

ISSN (Electronic): 1097-6787

ISSN (Print): 0190-9622

Publication date (Electronic): Mar 2017

Volume: 76

Issue: 3

Affiliations

[1 ] Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com.

[2 ] K. Papp Clinical Research and Probity Research Inc, Waterloo, Ontario, Canada.

[3 ] Dermatology Center, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Center, Manchester, United Kingdom.

[4 ] Janssen Research & Development LLC, Spring House, Pennsylvania; Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

[5 ] Janssen Research & Development LLC, Spring House, Pennsylvania.

[6 ] Department of Dermatology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Article

Publisher Item ID: S0190-9622(16)31157-4

DOI: 10.1016/j.jaad.2016.11.041

PubMed ID: 28057360

SO-VID: 1d24a590-6495-4305-a9c0-af8d5ec6d8ac

History

Keywords: VOYAGE 1,VOYAGE 2,adalimumab,efficacy,guselkumab,hand and foot psoriasis,nail psoriasis,psoriasis,safety,scalp psoriasis

Data availability:

Keywords: VOYAGE 1, VOYAGE 2, adalimumab, efficacy, guselkumab, hand and foot psoriasis, nail psoriasis, psoriasis, safety, scalp psoriasis

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.

Read this article at

Abstract

Related collections

Scientific Ocean Drilling Expedition Research Results

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 289